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Background
The Phase 2a HVTN 205 trial was undertaken to further
compare full-dose regimens of DNA priming with MVA
boosting and MVA priming and boosting.
Methods
150 vaccinia-naïve participants were inoculated i.m. via
needle and syringe with 3 mg of pGA2/JS7 DNA at
months 0 and 2, and 1x108 TCID50 of MVA/HIV62B at
months 4 and 6 (DDMM regimen). 75 participants
received 1x108 TCID50 of MVA/HIV62B at months 0, 2,
and 6 (MMM regimen) and 75 received placebo. While
the safety data are still blinded, the vaccine regimens
appeared safe and well tolerated. Immune studies were
performed at 2 weeks following the final vaccination.
Results
Similar to Phase 1 testing, the DDMM regimen induced
higher rates of T cell responses whereas the MMM regi-
men induced higher rates of antibody responses. CD4
T cell responses were elicited in 65% of the DDMM and
43% of the MMM recipients (p=0.01) whereas CD8 T cells
were induced in 22% and 16%, respectively. The majority
of T cells were directed against Gag with fewer against
Env and only occasional responses to Pol. gp120 IgG anti-
bodies were demonstrated in 45% and 68% of the DDMM
and MMM recipients, respectively (p=0.001). gp41 IgG
antibodies were seen in over 90% of both groups. The
magnitudes of serum IgG responses exceeded the magni-
tudes of serum IgA responses by >10 fold with higher IgG
to IgA responses being present in the MMM group
(p=0.03). The antibody avidity index to the gp41 immuno-
dominant epitope, a preclinical correlate of protection
against infection demonstrated levels of affinity maturation
comparable to preclinical studies. Sporadic weak neutraliz-
ing activity against Tier 1 and Tier 2 viruses was seen in
both groups and was greater for MVA alone.
Conclusion
The vaccine safety data and immune responses seen
here are supportive of further testing.
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